Antibody-Drug Conjugates for Platinum-Resistant Ovarian Cancer

EP: 1.The Role of Guidelines on Molecular Testing in Ovarian Cancer

EP: 2.FRα Biomarker Testing in Patients With Ovarian Cancer

EP: 3.Emerging Molecular Biomarkers in Ovarian Cancer

EP: 4.Comprehensive Molecular Testing in Patients With Ovarian Cancer

EP: 5.The Impact of Tumor Heterogeneity in Ovarian Cancer

EP: 6.Improving Clinician Awareness and Adoption of Molecular Testing

Now Viewing

EP: 7.Antibody-Drug Conjugates for Platinum-Resistant Ovarian Cancer

EP: 8.The Role of Novel Targeted Therapies

EP: 9.The Use of PARP Inhibitors in Ovarian Cancer

EP: 10.Earlier Introduction of Antibody-Drug Conjugates

EP: 11.Approaching Treatment Sequencing In Heavily Pretreated Patients

EP: 12.Single-Agent Vs Combination Regimens

EP: 13.The Potential Impact of Investigational Therapies

EP: 14.Learnings From Key Clinical Trials in Ovarian Cancer

Video content is prompted by the following:

Sequencing Antibody-Drug Conjugates in Platinum-Resistant Ovarian Cancer

Panelist Introduction

AJMC Insights Series features Kathleen Moore, MD, MS, a gynecologic oncologist and expert in ovarian cancer treatment. Dr Moore discusses various aspects of novel therapies for ovarian cancer treatment across 4 interview segments.

Expert Background

Kathleen Moore, MD, MS

• Specialty: Gynecologic oncology with focus on ovarian cancer therapies
• Experience: Clinical researcher with extensive experience in clinical trials for novel therapeutics
• Expertise areas: Antibody-drug conjugates, PARP inhibitors, and treatment sequencing strategies

Key Themes:

• Optimal placement of mirvetuximab soravtansine in treatment sequence
• Importance of folate receptor alpha testing
• Evolution from historical ineffective therapies to novel effective options

Notable Insights:

• Dr Moore recommends mirvetuximab as first-line therapy for platinum-resistant ovarian cancer in patients with folate receptor alpha-high tumors (defined as ≥75% of cells with 2+ staining intensity).
• Approximately 35% to 40% of high-grade serous ovarian cancers express high levels of folate receptor alpha.
• Historical therapies for platinum-resistant disease (weekly paclitaxel, pegylated liposomal doxorubicin, topotecan, gemcitabine) demonstrated limited efficacy, making sequencing less important previously.
• With the advent of effective therapies like mirvetuximab, sequencing decisions become more crucial but require further study.

Dr Moore noted: “For a patient who’s folate receptor alpha–high, use of mirvetuximab is the first line of therapy in the setting of platinum resistance...likely the optimal place to use this just because with most things that we see that are effective, the earlier you use them, the higher the response rate and the longer the duration of response.”